Search
Search
Search results 64
AmoyDx ROS1 Kit Got Approval in Taiwan
News & Events
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib
News & Events
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
News & Events
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
News & Events
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us.  The exhibition details are below.
News & Events
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China)  Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685)  announced that NMPA(National Medical Products Administration)approved AmoyDx Super-ARMS® EGFR mutation test kit
News & Events
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
News & Events
AmoyDx Distributors Annual Meeting (Europe) 2017
AmoyDx Distributors Annual Meeting (Europe) 2017 was held in Dusseldorf, Germany on November 15. Distributors from different European countries gathered to get the recent update on precision oncology
News & Events
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
News & Events
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
News & Events
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
News & Events
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
News & Events
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
News & Events
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
News & Events
AmoyDx HER2 Mutation Test Acting as Companion Diagnostics for Boehringer Ingelheim's Afatinib Study in NSCLC Patients
Recently Boehringer Ingelheim launched a Phase II study of Afatinib (Identifier: NCT02597946) to evaluate its efficacy and safety in advanced patients with advanced Non-Small Cell Lung Cancer (NSCLC)
News & Events
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
News & Events
Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China
· Blood-based EGFR mutation testing with AmoyDx’s novel and highly sensitive real-time PCR technology, SuperARMS®, will be made available in China in 2017.
News & Events
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection
News & Events
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
News & Events
Super-ARMS® EGFR Mutation Detection Kit
The best solution for Plasma EGFR Mutation Testing
PRODUCTS
EGFR 29 Mutations Detection Kit
PRODUCTS
EGFR/ALK/ROS1 Mutations Detection Kit
PRODUCTS
KRAS Mutation Detection Kit
PRODUCTS
KRAS/NRAS Mutations Detection Kit
PRODUCTS
KRAS/NRAS/BRAF Mutations Detection Kit
PRODUCTS
Essential NGS Panel
A precise NGS panel, focusing on 10 genes which have clear evidence to the targeted therapy.
PRODUCTS
HER-2 Gene Amplification Analysis Kit
PRODUCTS
P-EGFR-L2-02 Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma – Interlaboratory Quality Assessment in the Czech Republic
DOWNLOAD
P-EGFR-L2-01 Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)
DOWNLOAD
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
DOWNLOAD
EGFR-L2-06 EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with
DOWNLOAD
EGFR-L2-05 Gefitinib Treatment in EGFR Mutated Caucasian NSCLC Circulating-Free Tumor DNA as a Surrogate for Determination
DOWNLOAD
EGFR-L2-04 Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays
DOWNLOAD
EGFR-L2-03 EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma
DOWNLOAD
EGFR-L2-02 Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma A case report
DOWNLOAD
EGFR-L2-01 Molecular pathology in lung cancer a guide to the techniques used in clinical practice
DOWNLOAD
BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF
DOWNLOAD
MSDS-Super-ARMS EGFR-201804
DOWNLOAD
MSDS-Super-ARMS EGFR T790M-201804
DOWNLOAD
Super-ARMS® EGFR C797S Mutation Detection Kit-B1.0-12T
DOWNLOAD
MSDS-Super-ARMS EGFR Color Compensation kit -201804
DOWNLOAD
P-T790M-L1-01 Detection of EGFR T790M in Asia-Pacific patients with EGFR mutation-positive advanced NSCLC circulating tumour DNA
DOWNLOAD
P-EGFR-L1-03 Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung
DOWNLOAD
P-EGFR-L1-02 Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC
DOWNLOAD
P-EGFR-L1-01 Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients
DOWNLOAD
AmoyDx® EGFR.ALK.ROS1 Mutations Detection Kit-P2.2-8T
DOWNLOAD
HER2-L1-01 Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
DOWNLOAD
MSDS-EGFR-201804
DOWNLOAD
EGFR-L1-06 EML4-ALK-L1-01 Intratumoral Heterogeneity of ALK-Rearranged and ALK_EGFR Coaltered Lung Adenocarcinoma
DOWNLOAD
MSDS-EGFR ALK ROS1-201804
DOWNLOAD
EGFR-L1-05 Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS
DOWNLOAD
Super-ARMS® EGFR T790M Mutation Detection Kit-B2.2-24T
DOWNLOAD
EGFR-L1-04 Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
DOWNLOAD
Super-ARMS® EGFR Mutation Detection Kit-B1.2-12T
DOWNLOAD
EGFR-L1-03 ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens
DOWNLOAD
Color Compensation Instruction for P-EGFR-B1.1-J-12T
DOWNLOAD
EGFR-L1-02 Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases
DOWNLOAD
AmoyDx® EGFR 29 Mutations Detection Kit-B3.2-24T-CE-RGQ
DOWNLOAD
2. EGFR-2017.9
DOWNLOAD
EGFR-L1-01 The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation
DOWNLOAD
AmoyDx® EGFR 29 Mutations Detection Kit-B4.3-24T
DOWNLOAD
no more...
AmoyDx ROS1 Kit Got Approval in Taiwan
News & Events
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib
News & Events
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
News & Events
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
News & Events
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us.  The exhibition details are below.
News & Events
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China)  Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685)  announced that NMPA(National Medical Products Administration)approved AmoyDx Super-ARMS® EGFR mutation test kit
News & Events
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
News & Events
AmoyDx Distributors Annual Meeting (Europe) 2017
AmoyDx Distributors Annual Meeting (Europe) 2017 was held in Dusseldorf, Germany on November 15. Distributors from different European countries gathered to get the recent update on precision oncology
News & Events
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
News & Events
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
News & Events
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
News & Events
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
News & Events
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
News & Events
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
News & Events
AmoyDx HER2 Mutation Test Acting as Companion Diagnostics for Boehringer Ingelheim's Afatinib Study in NSCLC Patients
Recently Boehringer Ingelheim launched a Phase II study of Afatinib (Identifier: NCT02597946) to evaluate its efficacy and safety in advanced patients with advanced Non-Small Cell Lung Cancer (NSCLC)
News & Events
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
News & Events
Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China
· Blood-based EGFR mutation testing with AmoyDx’s novel and highly sensitive real-time PCR technology, SuperARMS®, will be made available in China in 2017.
News & Events
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection
News & Events
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
News & Events
no more...
P-EGFR-L2-02 Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma – Interlaboratory Quality Assessment in the Czech Republic
DOWNLOAD
P-EGFR-L2-01 Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)
DOWNLOAD
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
DOWNLOAD
EGFR-L2-06 EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with
DOWNLOAD
EGFR-L2-05 Gefitinib Treatment in EGFR Mutated Caucasian NSCLC Circulating-Free Tumor DNA as a Surrogate for Determination
DOWNLOAD
EGFR-L2-04 Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays
DOWNLOAD
EGFR-L2-03 EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma
DOWNLOAD
EGFR-L2-02 Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma A case report
DOWNLOAD
EGFR-L2-01 Molecular pathology in lung cancer a guide to the techniques used in clinical practice
DOWNLOAD
BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF
DOWNLOAD
MSDS-Super-ARMS EGFR-201804
DOWNLOAD
MSDS-Super-ARMS EGFR T790M-201804
DOWNLOAD
Super-ARMS® EGFR C797S Mutation Detection Kit-B1.0-12T
DOWNLOAD
MSDS-Super-ARMS EGFR Color Compensation kit -201804
DOWNLOAD
P-T790M-L1-01 Detection of EGFR T790M in Asia-Pacific patients with EGFR mutation-positive advanced NSCLC circulating tumour DNA
DOWNLOAD
P-EGFR-L1-03 Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung
DOWNLOAD
P-EGFR-L1-02 Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC
DOWNLOAD
P-EGFR-L1-01 Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients
DOWNLOAD
AmoyDx® EGFR.ALK.ROS1 Mutations Detection Kit-P2.2-8T
DOWNLOAD
HER2-L1-01 Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
DOWNLOAD
MSDS-EGFR-201804
DOWNLOAD
EGFR-L1-06 EML4-ALK-L1-01 Intratumoral Heterogeneity of ALK-Rearranged and ALK_EGFR Coaltered Lung Adenocarcinoma
DOWNLOAD
MSDS-EGFR ALK ROS1-201804
DOWNLOAD
EGFR-L1-05 Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS
DOWNLOAD
Super-ARMS® EGFR T790M Mutation Detection Kit-B2.2-24T
DOWNLOAD
EGFR-L1-04 Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
DOWNLOAD
Super-ARMS® EGFR Mutation Detection Kit-B1.2-12T
DOWNLOAD
EGFR-L1-03 ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens
DOWNLOAD
Color Compensation Instruction for P-EGFR-B1.1-J-12T
DOWNLOAD
EGFR-L1-02 Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases
DOWNLOAD
AmoyDx® EGFR 29 Mutations Detection Kit-B3.2-24T-CE-RGQ
DOWNLOAD
2. EGFR-2017.9
DOWNLOAD
EGFR-L1-01 The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation
DOWNLOAD
AmoyDx® EGFR 29 Mutations Detection Kit-B4.3-24T
DOWNLOAD
no more...
Inquiry
* Required information
Manage your account info
Change your password